Last edition
News about "Niopeg is a biosimilar to Neulasta (Pegfilgrastim)"
Sunshine Biopharma Enters Canadian Biosimilars Market with Launch of Niopeg
Niopeg is a biosimilar to Neulasta (Pegfilgrastim), a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor (filgrastim), used to reduce infection risk in cancer patients undergoing chemotherapy.
Niopeg Is A Biosimilar To Neulasta (Pegfilgrastim) | 04/07/2025 | By Darshana | 227
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members